DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

To Know in detail about the Metastatic Colorectal Cancer market outlook, drug uptake, treatment scenario ... ENHERTU was approved in the US as the first tumor-agnostic HER2-directed therapy ...

Our study highlights nonmedical factors that affect treatment access for many colorectal cancer patients, especially metastatic patients. Some of those barriers do include financial constraints.

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

CAMBRIDGE, Mass. - Leap Therapeutics, Inc. (NASDAQ:LPTX), a clinical-stage biotech company with a market capitalization of $86 million and an overall "Fair" financial health rating according to ...

Fueled by rising colorectal cancer ... trend toward early cancer detection and personalized treatment approaches, positioning Qiagen strongly in this expanding market. .October 2024: Roche ...

Colorectal cancer remains the third most common malignancy worldwide, with advanced stages presenting significant challenges for treatment. A recently published study highlights the potential of ...

it’s possible to prevent colorectal cancer. In fact, the earlier you get treatment, the easier the cancer is to cure. Experts recommend that most people at average risk get screened for ...

Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS ...

Amgen announced that the US Food ... Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, comprising 11% of all cancer diagnoses. It is also the third most commonly ...

That will affect your treatment options and what you can expect -- or as doctors say, your prognosis. Both colon and rectal cancer affect the large intestine, which is the lowest part of the ...